Phase 3 Study of Radiprodil in GRIN-related Neurodevelopmental Disorder Initiated
The Phase 3 trial for radiprodil in GRIN-NDD has commenced, focusing on efficacy and safety in two cohorts.
Company
Pharmaceutical intelligence for GRIN Therapeutics, Inc. with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.